StonvexLoading…
StonvexStonvexStonvexCore line items from TBI's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-29 | Annual 2025 2025-12-28 | Q3 2025 2025-09-28 | Q2 2025 2025-06-29 |
|---|---|---|---|---|
Revenue | $398.57M | $1.62B | $1.20B | $766.55M |
Operating Income | $-17.85M | $-46.63M | $-17.21M | $-17.06M |
Net Income | $-19.80M | $-47.96M | $-16.42M | $-14.51M |
EPS (Diluted) | $-0.66 | $-1.61 | $-0.55 | $-0.49 |
Total Assets | $620.67M | $638.67M | $690.53M | $672.78M |
Total Liabilities | $364.59M | $364.11M | $386.19M | $367.59M |
Cash & Equivalents | $24.13M | $24.51M | $19.89M | $21.90M |
Free Cash Flow OCF − CapEx | $-12.61M | $-73.72M | $-66.23M | $-42.84M |
Shares Outstanding | 30.38M | 29.99M | 29.92M | 29.89M |